Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M, Imanishi S, Hashimoto A, Wada H, Seino KI. Kajihara N, et al. Among authors: kobayashi t. Cancer Immunol Immunother. 2023 Apr;72(4):851-864. doi: 10.1007/s00262-022-03293-3. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36104597 Free PMC article.
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma.
Han N, Baghdadi M, Ishikawa K, Endo H, Kobayashi T, Wada H, Imafuku K, Hata H, Seino KI. Han N, et al. Among authors: kobayashi t. Inflamm Regen. 2018 Mar 5;38:3. doi: 10.1186/s41232-018-0060-2. eCollection 2018. Inflamm Regen. 2018. PMID: 29515691 Free PMC article.
Interleukin-34, a comprehensive review.
Baghdadi M, Umeyama Y, Hama N, Kobayashi T, Han N, Wada H, Seino KI. Baghdadi M, et al. Among authors: kobayashi t. J Leukoc Biol. 2018 Nov;104(5):931-951. doi: 10.1002/JLB.MR1117-457R. Epub 2018 Aug 1. J Leukoc Biol. 2018. PMID: 30066957 Review.
A role for IL-34 in osteolytic disease of multiple myeloma.
Baghdadi M, Ishikawa K, Nakanishi S, Murata T, Umeyama Y, Kobayashi T, Kameda Y, Endo H, Wada H, Bogen B, Yamamoto S, Yamaguchi K, Kasahara I, Iwasaki H, Takahata M, Ibata M, Takahashi S, Goto H, Teshima T, Seino KI. Baghdadi M, et al. Among authors: kobayashi t. Blood Adv. 2019 Feb 26;3(4):541-551. doi: 10.1182/bloodadvances.2018020008. Blood Adv. 2019. PMID: 30782613 Free PMC article.
Prognostic value of IL-34 in colorectal cancer patients.
Kobayashi T, Baghdadi M, Han N, Murata T, Hama N, Otsuka R, Wada H, Shiozawa M, Yokose T, Miyagi Y, Takano A, Daigo Y, Seino KI. Kobayashi T, et al. Immunol Med. 2019 Dec;42(4):169-175. doi: 10.1080/25785826.2019.1691429. Epub 2019 Nov 23. Immunol Med. 2019. PMID: 31762401
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.
Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI. Hama N, et al. Among authors: kobayashi t. iScience. 2020 Sep 19;23(10):101584. doi: 10.1016/j.isci.2020.101584. eCollection 2020 Oct 23. iScience. 2020. PMID: 33205010 Free PMC article.
Erratum: Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.
Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI. Hama N, et al. Among authors: kobayashi t. iScience. 2022 Jan 5;25(1):103713. doi: 10.1016/j.isci.2021.103713. eCollection 2022 Jan 21. iScience. 2022. PMID: 35028541 Free PMC article.
14,547 results
You have reached the last available page of results. Please see the User Guide for more information.